Cargando…

Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection

BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enh...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Himanshu, Yeh, Rose, Watts, Douglas M., Mehmetoglu-Gurbuz, Tugba, Resendes, Robert, Parsons, Bruce, Gonzales, Fernando, Joshi, Anjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796652/
https://www.ncbi.nlm.nih.gov/pubmed/33421988
http://dx.doi.org/10.1186/s12865-020-00389-2
_version_ 1783634729451388928
author Garg, Himanshu
Yeh, Rose
Watts, Douglas M.
Mehmetoglu-Gurbuz, Tugba
Resendes, Robert
Parsons, Bruce
Gonzales, Fernando
Joshi, Anjali
author_facet Garg, Himanshu
Yeh, Rose
Watts, Douglas M.
Mehmetoglu-Gurbuz, Tugba
Resendes, Robert
Parsons, Bruce
Gonzales, Fernando
Joshi, Anjali
author_sort Garg, Himanshu
collection PubMed
description BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enhancement (ADE) via cross reactive antibodies to flaviviruses like West Nile Virus (WNV) and Dengue Virus (DENV). Asymptomatic WNV infections are endemic throughout the US creating a large proportion of the population that is seropositive for WNV antibodies. Whether these sero-positive individuals potentially carry ZIKV enhancing antibodies remains unknown. RESULTS: Serum samples obtained from human subjects with symptomatic or asymptomatic WNV infection from a WNV endemic region in Texas were tested for their ability to enhance or neutralize ZIKV infection. Sero-surveillance data demonstrated a ~ 7% prevalence for WNV antibodies in the population. Sera from both symptomatic and asymptomatic WNV seropositive donors effectively neutralized WNV and to some extent DENV infection. Interestingly, WNV+ sera failed to inhibit ZIKV while significantly enhancing infection. Conversely, ZIKV specific sera effectively neutralized ZIKV, with ADE only evident at lower concentrations. The enhancement of ZIKV via WNV antibody positive sera was likely due to non-neutralizing Envelope (E) antibodies as seen with monoclonal ZIKV E antibodies. CONCLUSIONS: Overall, our findings suggest that WNV antibodies in the sera significantly enhance ZIKV infection in Fc receptor positive cells with limited neutralization activity. Further studies in more relevant models of ADE will be needed to confirm the relevance of these findings in vivo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-020-00389-2.
format Online
Article
Text
id pubmed-7796652
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77966522021-01-11 Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection Garg, Himanshu Yeh, Rose Watts, Douglas M. Mehmetoglu-Gurbuz, Tugba Resendes, Robert Parsons, Bruce Gonzales, Fernando Joshi, Anjali BMC Immunol Research Article BACKGROUND: Recent outbreaks of Zika Virus (ZIKV) infection and associated microcephaly has raised multiple scientific questions. The close antigenic relatedness between flaviviruses makes diagnosis of specific infection difficult. This relatedness also raises the potential of Antibody Dependent Enhancement (ADE) via cross reactive antibodies to flaviviruses like West Nile Virus (WNV) and Dengue Virus (DENV). Asymptomatic WNV infections are endemic throughout the US creating a large proportion of the population that is seropositive for WNV antibodies. Whether these sero-positive individuals potentially carry ZIKV enhancing antibodies remains unknown. RESULTS: Serum samples obtained from human subjects with symptomatic or asymptomatic WNV infection from a WNV endemic region in Texas were tested for their ability to enhance or neutralize ZIKV infection. Sero-surveillance data demonstrated a ~ 7% prevalence for WNV antibodies in the population. Sera from both symptomatic and asymptomatic WNV seropositive donors effectively neutralized WNV and to some extent DENV infection. Interestingly, WNV+ sera failed to inhibit ZIKV while significantly enhancing infection. Conversely, ZIKV specific sera effectively neutralized ZIKV, with ADE only evident at lower concentrations. The enhancement of ZIKV via WNV antibody positive sera was likely due to non-neutralizing Envelope (E) antibodies as seen with monoclonal ZIKV E antibodies. CONCLUSIONS: Overall, our findings suggest that WNV antibodies in the sera significantly enhance ZIKV infection in Fc receptor positive cells with limited neutralization activity. Further studies in more relevant models of ADE will be needed to confirm the relevance of these findings in vivo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-020-00389-2. BioMed Central 2021-01-09 /pmc/articles/PMC7796652/ /pubmed/33421988 http://dx.doi.org/10.1186/s12865-020-00389-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Garg, Himanshu
Yeh, Rose
Watts, Douglas M.
Mehmetoglu-Gurbuz, Tugba
Resendes, Robert
Parsons, Bruce
Gonzales, Fernando
Joshi, Anjali
Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title_full Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title_fullStr Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title_full_unstemmed Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title_short Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection
title_sort enhancement of zika virus infection by antibodies from west nile virus seropositive individuals with no history of clinical infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796652/
https://www.ncbi.nlm.nih.gov/pubmed/33421988
http://dx.doi.org/10.1186/s12865-020-00389-2
work_keys_str_mv AT garghimanshu enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT yehrose enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT wattsdouglasm enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT mehmetoglugurbuztugba enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT resendesrobert enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT parsonsbruce enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT gonzalesfernando enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection
AT joshianjali enhancementofzikavirusinfectionbyantibodiesfromwestnilevirusseropositiveindividualswithnohistoryofclinicalinfection